Skip to main content
All lobbying filings

FRESENIUS KABI USA LLC

Lobbying for FRESENIUS KABI USA LLC

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · Illinois · House · Senate · $430,000.00 expenses · posted Jan 20, 2026

Official filing document

 Bills named in this filing 5
 Lobbying activity 5
Medicare/Medicaid

Drug Shortages and Medicaid Specialty Drug Pharmacy Payment Reform

Health Issues

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act S. 1414/H.R._: Expedited Access to Biosimilars Act S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act US Drug Enforcement Administration Quota FDA/PTO Coordination USPTO Practices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Domestic Manufacturing Tariffs Medical Devices Generic Medicines Industry Net Effective Cost Biosimilar User Fee Act (BsUFA) Drug Shortages Domestic Manufacturing

Manufacturing

Domestic Manufacturing

Copyright/Patent/Trademark

PTAB Discretionary Denials

Trade (domestic/foreign)

Drug Shortages Domestic Manufacturing Tariffs Medical Devices Most Favored Nation (MFN) Proposed Rule Biosimilar Tariffs Generic Medicines

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem